You are here

Drug Forecast

A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The First FDA-Approved Treatment for Tardive Dyskinesia
A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections
A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor
A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis
The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection
A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes
A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson’s Disease
An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype
A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea
A Treatment for Hallucinations and Delusions Associated With Parkinson’s Disease
The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women
A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting
A Novel Adjunctive Therapy for Partial-Onset Seizures
A Treatment Option for Chronic Hepatitis C Infection
A Review of Clinical Efficacy and Safety in Epilepsy
An Extended-Release, Long-Acting Injection For the Treatment of Schizophrenia
For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections
A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder

Pages